Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

NCT03000660 is registered in ClinicalTrials.gov with Tufts Medical Center as lead sponsor.

NCT NCT03000660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03000660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Lead sponsor
Tufts Medical Center
Phase
Phase 1
Overall status
Terminated
Start date
January 31, 2017
Completion date
October 10, 2019
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis